WO2001059078A3 - Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates - Google Patents
Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates Download PDFInfo
- Publication number
- WO2001059078A3 WO2001059078A3 PCT/US2001/040069 US0140069W WO0159078A3 WO 2001059078 A3 WO2001059078 A3 WO 2001059078A3 US 0140069 W US0140069 W US 0140069W WO 0159078 A3 WO0159078 A3 WO 0159078A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- urate oxidase
- aggregate
- preparation
- polymer conjugates
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60141742T DE60141742D1 (en) | 2000-02-10 | 2001-02-07 | AGGREGATE-FREE HARNIC ACID OXIDASE FOR PREPARING NON-IMMUNOGENIC POLYMERIC CONJUGATES |
MXPA02007545A MXPA02007545A (en) | 2000-02-10 | 2001-02-07 | Aggregate free urate oxidase for preparation of non immunogenic polymer conjugates. |
NZ520434A NZ520434A (en) | 2000-02-10 | 2001-02-07 | Urate oxidase free of aggregates larger than octamers, for preparation of non-immunogenic polymer conjugates |
AU2001249975A AU2001249975B2 (en) | 2000-02-10 | 2001-02-07 | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
IL15106501A IL151065A0 (en) | 2000-02-10 | 2001-02-07 | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
AU4997501A AU4997501A (en) | 2000-02-10 | 2001-02-07 | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
HU0204544A HU227127B1 (en) | 2000-02-10 | 2001-02-07 | Purified urate oxidases, process for preparation thereof and uricase conjugates |
AT01923265T ATE463576T1 (en) | 2000-02-10 | 2001-02-07 | AGGREGATE-FREE URIC ACID OXIDASE FOR THE PRODUCTION OF NON-IMMUNOGENIC POLYMER CONJUGATES |
KR1020087024272A KR101054247B1 (en) | 2000-02-10 | 2001-02-07 | Purified urate oxidase preparation, composition comprising the same, and purifying method thereof |
CA2398679A CA2398679C (en) | 2000-02-10 | 2001-02-07 | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
DK01923265.1T DK1254237T3 (en) | 2000-02-10 | 2001-02-07 | Aggregate-free urate oxidase to prepare non-immunogenic polymer conjugates |
EP01923265A EP1254237B1 (en) | 2000-02-10 | 2001-02-07 | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
JP2001558218A JP5165826B2 (en) | 2000-02-10 | 2001-02-07 | Aggregate-free urate oxidase for the preparation of non-immunogenic polymer conjugates |
ES01923265T ES2343105T3 (en) | 2000-02-10 | 2001-02-07 | URATO OXIDASA WITHOUT AGGREGATES FOR THE PREPARATION OF IMMUNOGENIC POLYMERIC CONJUGATES. |
BRPI0108386A BRPI0108386B8 (en) | 2000-02-10 | 2001-02-07 | uricase conjugate, pharmaceutical composition and method for the purification of uricase |
IL151065A IL151065A (en) | 2000-02-10 | 2002-08-05 | Aggregate-free urate oxidases, polymer conjugates thereof and compositions prepared therefrom |
HK03109064.9A HK1056742A1 (en) | 2000-02-10 | 2003-12-11 | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
AU2006203252A AU2006203252B8 (en) | 2000-02-10 | 2006-07-31 | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
IL193365A IL193365A (en) | 2000-02-10 | 2008-08-11 | Aggregate-free urate oxidases, polymer conjugates thereof and compositions prepared therefrom |
BE2013C045C BE2013C045I2 (en) | 2000-02-10 | 2013-07-03 | |
CY2013028C CY2013028I2 (en) | 2000-02-10 | 2013-07-04 | URIC OXIDATION OF FREE AGGREGATES FOR THE PREPARATION OF NON-IMMUNE CONJUGATES WITH POLYMERS |
FR13C0036C FR13C0036I2 (en) | 2000-02-10 | 2013-07-04 | AGGREGATE-FREE URATE OXIDASE FOR THE PREPARATION OF NON-IMMUNOGENIC CONJUGATED POLYMERS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/501,730 US6783965B1 (en) | 2000-02-10 | 2000-02-10 | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
US09/501,730 | 2000-02-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001059078A2 WO2001059078A2 (en) | 2001-08-16 |
WO2001059078A3 true WO2001059078A3 (en) | 2002-03-07 |
Family
ID=23994789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/040069 WO2001059078A2 (en) | 2000-02-10 | 2001-02-07 | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
Country Status (28)
Country | Link |
---|---|
US (3) | US6783965B1 (en) |
EP (3) | EP2305819B1 (en) |
JP (2) | JP5165826B2 (en) |
KR (3) | KR100884724B1 (en) |
CN (2) | CN101735991B (en) |
AT (1) | ATE463576T1 (en) |
AU (3) | AU2001249975B2 (en) |
BE (1) | BE2013C045I2 (en) |
BR (1) | BRPI0108386B8 (en) |
CA (1) | CA2398679C (en) |
CY (3) | CY1110142T1 (en) |
CZ (1) | CZ304864B6 (en) |
DE (1) | DE60141742D1 (en) |
DK (3) | DK1254237T3 (en) |
ES (2) | ES2343105T3 (en) |
FR (1) | FR13C0036I2 (en) |
HK (4) | HK1056742A1 (en) |
HU (1) | HU227127B1 (en) |
IL (3) | IL151065A0 (en) |
LU (1) | LU92237I2 (en) |
MX (1) | MXPA02007545A (en) |
NZ (1) | NZ520434A (en) |
PL (1) | PL208064B1 (en) |
PT (2) | PT2305819E (en) |
RU (3) | RU2281954C2 (en) |
TW (2) | TW200914617A (en) |
WO (1) | WO2001059078A2 (en) |
ZA (1) | ZA200207206B (en) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
RU2246318C2 (en) * | 1998-08-06 | 2005-02-20 | Маунтэн Вью Фармасьютикэлз, Инк. | Uricase peg-conjugates and their applying |
US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
PT1588716E (en) * | 1998-08-06 | 2011-05-25 | Mountain View Pharmaceuticals | Peg-urate oxidase conjugates and use thereof |
US20060188971A1 (en) * | 1998-08-06 | 2006-08-24 | Duke University | Urate oxidase |
WO2000008196A2 (en) | 1998-08-06 | 2000-02-17 | Duke University | Urate oxidase |
EP1421175B1 (en) | 2001-06-28 | 2008-11-19 | Mountain View Pharmaceuticals, Inc. | Polymer stabilized proteinases |
US6913915B2 (en) | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
DK1941867T3 (en) | 2002-06-07 | 2012-01-02 | Dyax Corp | Polypeptide with Modified Kunitz Domain |
US8129330B2 (en) * | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US20040062748A1 (en) | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
NZ541124A (en) * | 2002-12-26 | 2008-08-29 | Mountain View Pharmaceuticals | Polymer conjugates of interferon-beta with enhanced biological potency |
MXPA05012315A (en) * | 2003-05-12 | 2006-04-18 | Affymax Inc | Novel poly(ethylene glycol) modified compounds and uses thereof. |
WO2004100997A2 (en) * | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Spacer moiety for poly(ethylene glycol) -modified peptides |
KR101227666B1 (en) * | 2003-05-12 | 2013-01-31 | 아피맥스, 인크. | Peptides that bind to the erythropoietin receptor |
PT1663281E (en) * | 2003-08-29 | 2014-03-17 | Dyax Corp | Poly-pegylated protease inhibitors |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
EA200700990A1 (en) * | 2004-11-11 | 2008-04-28 | Афимакс, Инк. | NEW PEPTIDES THAT BIND THE ERYTHROPOIETIN RECEPTOR |
WO2006062685A2 (en) * | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
EP1868652A2 (en) * | 2005-04-05 | 2007-12-26 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Method for shielding functional sites or epitopes on proteins |
US20080159976A1 (en) * | 2005-04-11 | 2008-07-03 | Jacob Hartman | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
US7811800B2 (en) | 2005-04-11 | 2010-10-12 | Savient Pharmaceuticals, Inc. | Variant form of urate oxidase and use thereof |
US8148123B2 (en) * | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
JP2008535500A (en) | 2005-04-11 | 2008-09-04 | サビエント ファーマセウティカルズ インク. | Mutant urate oxidase and use thereof |
US20090081122A1 (en) * | 2005-05-23 | 2009-03-26 | Universite De Geneve | Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant |
US7550433B2 (en) * | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US7919461B2 (en) | 2005-06-03 | 2011-04-05 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US8324159B2 (en) * | 2005-06-03 | 2012-12-04 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
CN101622270B (en) * | 2006-04-12 | 2014-01-01 | 萨文特医药公司 | Method for purification of proteins with cationic surfactant |
WO2009026334A2 (en) * | 2007-08-21 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
AU2010203712A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
SG176897A1 (en) | 2009-06-25 | 2012-01-30 | Savient Pharmaceuticals Inc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
WO2011085103A2 (en) | 2010-01-06 | 2011-07-14 | Dyax Corp. | Plasma kallikrein binding proteins |
WO2011127393A2 (en) | 2010-04-08 | 2011-10-13 | Georgia Tech Research Corporation | Variants of ancestral uricases and uses thereof |
JP2014506257A (en) | 2011-01-06 | 2014-03-13 | ダイアックス コーポレーション | Plasma kallikrein binding protein |
CN102827073A (en) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | Therapeutically active compositions and application methods thereof |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
WO2014197806A2 (en) | 2013-06-07 | 2014-12-11 | Allena Pharmaceuticals, Inc. | Compositions, methods, and devices for dialysis |
JP6529492B2 (en) | 2013-07-11 | 2019-06-12 | アジオス ファーマシューティカルズ, インコーポレイテッド | 2,4- or 4,6-Diaminopyrimidine Compounds as IDH2 Mutant Inhibitors for the Treatment of Cancer |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
AU2015229214B2 (en) | 2014-03-14 | 2019-07-11 | Les Laboratoires Servier | Pharmaceutical compositions of therapeutically active compounds |
AU2015235967B2 (en) | 2014-03-27 | 2020-10-22 | Takeda Pharmaceutical Company Limited | Compositions and methods for treatment of diabetic macular edema |
AU2016265677B2 (en) | 2015-05-15 | 2021-12-09 | Medimmune, Llc | Improved uricase sequences and methods of treatment |
CA3216701A1 (en) | 2015-10-15 | 2017-04-20 | Les Laboratoires Servier | Combination therapy for treating malignancies |
BR112018007656A2 (en) | 2015-10-15 | 2018-11-06 | Agios Pharmaceuticals Inc | combination therapy for treatment of malignant diseases |
US11286307B2 (en) | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
CN116637177A (en) | 2016-11-11 | 2023-08-25 | 好利恩治疗美国公司 | Combination therapy of prednisone and uricase molecules and uses thereof |
CN111373034A (en) | 2017-07-07 | 2020-07-03 | 艾乐娜制药有限公司 | Recombinant uricase |
US20190309269A1 (en) | 2018-03-20 | 2019-10-10 | Rubius Therapeutics, Inc. | Therapeutic cell systems and methods for treating hyperuricemia and gout |
US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
CN109055260B (en) * | 2018-08-08 | 2021-11-09 | 淮海工学院 | Bacillus flexus alkaAU and method for producing urate oxidase, product and application |
CN114181917B (en) * | 2022-02-14 | 2022-06-03 | 潍坊华卓生物科技有限公司 | Modified uricase, gene sequence, preparation method and application |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000007629A2 (en) * | 1998-08-06 | 2000-02-17 | Mountain View Pharmaceuticals, Inc. | Peg-urate oxidase conjugates and use thereof |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE279486C (en) | ||||
US3616231A (en) | 1968-11-14 | 1971-10-26 | Boehringer Mannheim Gmbh | Process for the production of uricase |
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS5599189A (en) | 1979-01-22 | 1980-07-28 | Mihama Hisaharu | Modified uricase free from antigenicity and its preparation |
JPS55135590A (en) | 1979-04-05 | 1980-10-22 | Mihama Hisaharu | Modified asparaginase and uricase and their preparation |
CH651308A5 (en) | 1980-07-01 | 1985-09-13 | Hoffmann La Roche | INTERFERON AND THEIR PRODUCTION. |
JPS57192435A (en) | 1981-05-20 | 1982-11-26 | Toyobo Co Ltd | Modified polypeptide |
DE3126759A1 (en) | 1981-07-07 | 1983-01-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | SOLUBLE LIVER URICASE, METHOD FOR THE PRODUCTION AND USE THEREOF |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
WO1987000056A1 (en) * | 1985-06-26 | 1987-01-15 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
US4847079A (en) * | 1985-07-29 | 1989-07-11 | Schering Corporation | Biologically stable interferon compositions comprising thimerosal |
DD279486A1 (en) | 1986-03-10 | 1990-06-06 | Akad Wissenschaften Ddr | PROCESS FOR ACTIVATING HYDROXYL GROUP-CONTAINING POLYMER COMPOUNDS |
JPS6255079A (en) * | 1986-04-23 | 1987-03-10 | Mihama Hisaharu | Modified uricase |
JPH085506B2 (en) * | 1986-08-25 | 1996-01-24 | 日東製器株式会社 | Can container |
DD279489A1 (en) | 1986-12-11 | 1990-06-06 | Leuna Werke Veb | METHOD FOR PRODUCING OPTICALLY TRANSPARENT EPOXY RESIN COMPOSITIONS |
US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
US5955336A (en) * | 1988-08-17 | 1999-09-21 | Toyo Boseki Kabushiki Kaisha | DNA sequence for uricase and manufacturing process of uricase |
US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
NZ234453A (en) * | 1989-07-13 | 1993-01-27 | Sanofi Sa | Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith |
US5382518A (en) | 1989-07-13 | 1995-01-17 | Sanofi | Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells |
US5286637A (en) | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
JPH03148298A (en) | 1989-11-01 | 1991-06-25 | Sumitomo Pharmaceut Co Ltd | Modified peptide and production thereof |
US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
US5653974A (en) | 1990-10-18 | 1997-08-05 | Board Of Regents,The University Of Texas System | Preparation and characterization of liposomal formulations of tumor necrosis factor |
ES2199935T3 (en) * | 1991-03-15 | 2004-03-01 | Amgen Inc. | PEGILATION OF POLYPEPTIDES. |
CA2112674C (en) | 1991-07-02 | 2005-10-04 | John S. Patton | Method and device for delivering aerosolized medicaments |
AU6240494A (en) | 1993-02-16 | 1994-09-14 | Enzon, Inc. | Ribosome inactivating protein compositions having reduced antigenicity |
WO1994023740A1 (en) * | 1993-04-22 | 1994-10-27 | Celtrix Pharmaceuticals, Inc. | Conjugates of growth factor and bone resorption inhibitor |
AU7113594A (en) | 1993-06-21 | 1995-01-17 | Enzon, Inc. | Site specific synthesis of conjugated peptides |
IT1265101B1 (en) * | 1993-07-23 | 1996-10-30 | Erba Carlo Spa | DERIVATIVES OF 2-AMINO-4-PHENYL-4-BUTYRIC BONE ACID |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5711944A (en) * | 1993-11-10 | 1998-01-27 | Enzon, Inc. | Interferon polymer conjugates |
US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
CA2206852A1 (en) * | 1994-12-07 | 1996-06-13 | Novo Nordisk A/S | Polypeptide with reduced allergenicity |
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
JP2758154B2 (en) * | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | Liquid preparations containing interferon |
FR2733914B1 (en) * | 1995-05-11 | 1997-08-01 | Sanofi Sa | STABLE LIQUID COMPOSITION CONTAINING URATE OXYDASE AND LYOPHILIZED COMPOSITION FOR ITS PREPARATION |
US5853974A (en) | 1995-06-07 | 1998-12-29 | Chiron Corporation | Enhancement of alkaline phosphatase with SDS in chemiluminescent substrates |
JPH09154581A (en) | 1995-12-05 | 1997-06-17 | Asahi Chem Ind Co Ltd | Substantially pure microorganism capable of producing uricase |
ES2275300T3 (en) | 1997-01-15 | 2007-06-01 | Phoenix Pharmacologics, Inc. | MODIFIED TUMOR NECROSIS FACTOR. |
DK1084136T3 (en) * | 1998-06-01 | 2005-01-03 | Genentech Inc | Separation of monomers by an antibody from its multimers using ion exchange chromatography |
PT1588716E (en) | 1998-08-06 | 2011-05-25 | Mountain View Pharmaceuticals | Peg-urate oxidase conjugates and use thereof |
US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
WO2000008196A2 (en) | 1998-08-06 | 2000-02-17 | Duke University | Urate oxidase |
US6425448B1 (en) | 2001-01-30 | 2002-07-30 | Cdx Gas, L.L.P. | Method and system for accessing subterranean zones from a limited surface area |
US6913915B2 (en) * | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
KR20160012187A (en) | 2013-05-24 | 2016-02-02 | 첸트룸 미크로엘렉트로닉 드레스덴 악치엔게젤샤프트 | Non pwm digital dc-dc converter |
-
2000
- 2000-02-10 US US09/501,730 patent/US6783965B1/en not_active Expired - Lifetime
-
2001
- 2001-02-06 TW TW097145974A patent/TW200914617A/en unknown
- 2001-02-06 TW TW090102540A patent/TWI322184B/en not_active IP Right Cessation
- 2001-02-07 PL PL358539A patent/PL208064B1/en unknown
- 2001-02-07 RU RU2002120486/13A patent/RU2281954C2/en not_active IP Right Cessation
- 2001-02-07 KR KR1020027010189A patent/KR100884724B1/en active IP Right Grant
- 2001-02-07 DK DK01923265.1T patent/DK1254237T3/en active
- 2001-02-07 CZ CZ2002-2982A patent/CZ304864B6/en not_active IP Right Cessation
- 2001-02-07 DE DE60141742T patent/DE60141742D1/en not_active Expired - Lifetime
- 2001-02-07 ES ES01923265T patent/ES2343105T3/en not_active Expired - Lifetime
- 2001-02-07 NZ NZ520434A patent/NZ520434A/en not_active IP Right Cessation
- 2001-02-07 MX MXPA02007545A patent/MXPA02007545A/en active IP Right Grant
- 2001-02-07 EP EP10180428.4A patent/EP2305819B1/en not_active Expired - Lifetime
- 2001-02-07 DK DK10180428.4T patent/DK2305819T3/en active
- 2001-02-07 AU AU2001249975A patent/AU2001249975B2/en not_active Revoked
- 2001-02-07 IL IL15106501A patent/IL151065A0/en unknown
- 2001-02-07 EP EP01923265A patent/EP1254237B1/en not_active Expired - Lifetime
- 2001-02-07 EP EP10158016.5A patent/EP2196538B1/en not_active Expired - Lifetime
- 2001-02-07 PT PT101804284T patent/PT2305819E/en unknown
- 2001-02-07 BR BRPI0108386A patent/BRPI0108386B8/en not_active Application Discontinuation
- 2001-02-07 HU HU0204544A patent/HU227127B1/en active Protection Beyond IP Right Term
- 2001-02-07 AU AU4997501A patent/AU4997501A/en active Pending
- 2001-02-07 ES ES10180428.4T patent/ES2524153T3/en not_active Expired - Lifetime
- 2001-02-07 WO PCT/US2001/040069 patent/WO2001059078A2/en active Application Filing
- 2001-02-07 RU RU2006107110/13A patent/RU2352354C2/en active
- 2001-02-07 KR KR1020087024272A patent/KR101054247B1/en active IP Right Grant
- 2001-02-07 CN CN2009101278530A patent/CN101735991B/en not_active Expired - Lifetime
- 2001-02-07 PT PT01923265T patent/PT1254237E/en unknown
- 2001-02-07 JP JP2001558218A patent/JP5165826B2/en not_active Expired - Lifetime
- 2001-02-07 CN CNB018077501A patent/CN100491532C/en not_active Expired - Lifetime
- 2001-02-07 CA CA2398679A patent/CA2398679C/en not_active Expired - Lifetime
- 2001-02-07 DK DK10158016.5T patent/DK2196538T3/en active
- 2001-02-07 KR KR1020077018682A patent/KR20070092329A/en active Search and Examination
- 2001-02-07 AT AT01923265T patent/ATE463576T1/en active
-
2002
- 2002-08-05 IL IL151065A patent/IL151065A/en active Protection Beyond IP Right Term
- 2002-09-09 ZA ZA200207206A patent/ZA200207206B/en unknown
-
2003
- 2003-12-11 HK HK03109064.9A patent/HK1056742A1/en not_active IP Right Cessation
-
2007
- 2007-08-03 US US11/882,750 patent/US7927852B2/en not_active Expired - Fee Related
-
2008
- 2008-08-11 IL IL193365A patent/IL193365A/en active IP Right Grant
-
2009
- 2009-02-06 RU RU2009104003/10A patent/RU2557318C9/en active
- 2009-09-02 AU AU2009212900A patent/AU2009212900B2/en not_active Expired
-
2010
- 2010-06-29 CY CY20101100597T patent/CY1110142T1/en unknown
- 2010-10-27 HK HK10110105.9A patent/HK1143989A1/en not_active IP Right Cessation
- 2010-10-27 HK HK11109405.7A patent/HK1155203A1/en not_active IP Right Cessation
- 2010-12-08 HK HK10111402.7A patent/HK1144701A1/en not_active IP Right Cessation
-
2011
- 2011-04-12 JP JP2011088663A patent/JP5341945B2/en not_active Expired - Lifetime
- 2011-04-13 US US13/085,793 patent/US8921064B2/en not_active Expired - Fee Related
-
2013
- 2013-07-03 LU LU92237C patent/LU92237I2/en unknown
- 2013-07-03 BE BE2013C045C patent/BE2013C045I2/fr unknown
- 2013-07-04 FR FR13C0036C patent/FR13C0036I2/en active Active
- 2013-07-04 CY CY2013028C patent/CY2013028I2/en unknown
-
2015
- 2015-02-09 CY CY20151100129T patent/CY1117264T1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000007629A2 (en) * | 1998-08-06 | 2000-02-17 | Mountain View Pharmaceuticals, Inc. | Peg-urate oxidase conjugates and use thereof |
Non-Patent Citations (9)
Title |
---|
BURNHAM N L: "POLYMERS FOR DELIVERING PEPTIDES AND PROTEINS", AMERICAN JOURNAL OF HOSPITAL PHARMACY, AMERICAN SOCIETY OF HOSPITAL PHARMACISTS, BETHESDA, MD, US, vol. 51, no. 2, 15 January 1994 (1994-01-15), pages 210 - 218, XP000783643, ISSN: 0002-9289 * |
CHEN R H-L ET AL: "PROPERTIES OF TWO URATE OXIDASES MODIFIED BY THE COVALENT ATTACHMENT OF POLY(ETHYLENE GLYCOL)", BBA ENZYMOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 660, no. 2, 13 August 1981 (1981-08-13), pages 293 - 298, XP000577602, ISSN: 0005-2744 * |
CHUA C C ET AL: "Use of polyethylene glycol-modified uricase ( PEG - uricase ) to treat hyperuricemia in a patient with non-Hodgkin lymphoma", ANNALS OF INTERNAL MEDICINE, NEW YORK, NY, US, 15 July 1988 (1988-07-15), pages 114 - 117, XP002125211, ISSN: 0003-4819 * |
DAVIS S ET AL: "HYPOURICAEMIC EFFECT OF POLYETHYLENEGLYCOL MODIFIED URATE OXIDASE", LANCET THE, LANCET LIMITED. LONDON, GB, 8 August 1981 (1981-08-08), pages 281 - 283, XP000577404, ISSN: 0140-6736 * |
MONTALBINI P ET AL: "URICASE FROM LEAVES: ITS PURIFICATION AND CHARACTERIZATION FROM THREE DIFFERENT HIGHER PLANTS", PLANTA, SPRINGER VERLAG, DE, vol. 202, no. 3, 8 January 1997 (1997-01-08), pages 277 - 283, XP000881523, ISSN: 0032-0935 * |
OSMAN A M ET AL: "Liver uricase in Camelus dromedarius: purification and properties", COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY. B. COMPARATIVE BIOCHEMISTRY, PERGAMON PRESS, LONDON, GB, vol. 94B, no. 3, 1989, pages 469 - 474, XP002125210, ISSN: 0305-0491 * |
SAVOCA K V ET AL: "Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modified uricase", INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, BASEL, CH, vol. 75, 1984, pages 58 - 67, XP002125212, ISSN: 0020-5915 * |
SUZUKI H ET AL: "SOYBEAN NODULE-SPECIFIC URICASE NODULIN 35 IS EXPRESSED AND ASSEMBLED INTO A FUNCTIONAL TETRAMERIC HOLOENZYME IN ESCHERICHIA-COLI", PLANT PHYSIOLOGY, AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, ROCKVILLE, MD, US, vol. 95, 1991, pages 384 - 389, XP002125213, ISSN: 0032-0889 * |
YASUDA Y ET AL: "Biochemical and biopharmaceutical properties of macromolecular conjugates of uricase with dextran and polyethylene glycol", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO, JP, vol. 38, no. 7, July 1990 (1990-07-01), pages 2053 - 2056, XP002125209, ISSN: 0009-2363 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001059078A3 (en) | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates | |
DK1180121T3 (en) | Long-acting insulinotropic peptides | |
CA2064689A1 (en) | Stabilized protein or peptide conjugates | |
WO2001093914A3 (en) | Multivalent platform molecules comprising high molecular weight polyethylene oxide | |
WO1999055377A3 (en) | Polyol-ifn-beta conjugates | |
EP1329458A3 (en) | Peptides that lower blood glucose levels | |
WO2003022208A3 (en) | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith | |
KR940019312A (en) | Lyophilized complex of cyclodextrin with protein and polypeptide modified with polyethylene oxide | |
JP2002527052A5 (en) | ||
PT1100542E (en) | PEG-URICASE OXIDASE CONJUGATE AND ITS USE | |
WO1998046257A8 (en) | Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods | |
EP1808155A3 (en) | Antibody-serum protein hybrids | |
WO2008027944A3 (en) | Antigenic protein conjugates and process for preparing same | |
EP0754229A1 (en) | Alfamin: a human serum albumin-like protein | |
WO2000070665A3 (en) | Long lasting anti-angiogenic peptides | |
EP1211311A3 (en) | Cord blood-derived activated lymphocytes and preparations containing said lymphocytes | |
AU4626096A (en) | Immunoenzymatic conjugate, preparation method therefor and uses thereof | |
WO2004091508A3 (en) | Fullerene compositions for ameliorating dermatological conditions | |
ATE376836T1 (en) | MUCIN PEPTIDE WITH IMMUNE-BOOSTING PROPERTIES | |
WO1998015293A3 (en) | Targeted addition of soluble polymers to recombinant proteins | |
CA2175578A1 (en) | Cell control and suppression | |
Appukuttan et al. | Glutaraldehyde cross-linking of lectins to marker enzymes: Protection of binding site by specific sugars | |
AU2002300605A1 (en) | Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods | |
Yuecel et al. | Increased susceptibility to oxidative stress in lens tissues of sulfur dioxide exposed rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2398679 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 520434 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2002/983/KOL Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/007545 Country of ref document: MX Ref document number: 151065 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027010189 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2001 558218 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001923265 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2002-2982 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001249975 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/07206 Country of ref document: ZA Ref document number: 200207206 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref document number: 2002 2002120486 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018077501 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2001923265 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027010189 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2002-2982 Country of ref document: CZ |
|
REG | Reference to national code |
Ref legal event code: 8642 Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 520434 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 520434 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 193365 Country of ref document: IL |